Chlamydia Infections – Pipeline Review, 2019

Chlamydia is a sexually transmitted disease that is caused due to the bacteria called Chlamydia trachomatis. The symptoms of the chlamydia infections are not seen in the early stages. In fact, about 90.0% of women and 70.0% of men with sexually transmitted diseases have no symptoms. According to Centers for Diseases Control and Prevention (CDC), in 2017, 1,127,651 cases of chlamydia were reported among females at a rate of 687.4 cases per 100,000 females. Multiple infections in females increases the chances of severe complications of the reproductive system, including ectopic pregnancy, and pelvic inflammatory disease.

Current treatment for chlamydia infections includes antibiotics. Food and Drug Administration (FDA) has approved azithromycin (Zithromax) and doxycycline for the treatment of chlamydia infections.

Research Institutes and pharmaceutical companies have focussed on studying and developing new methods for the treatment of chlamydia infections. For instance; CTH522-CAF01, which is being studied by the Statens Serum Institute in collaboration with Imperial College London is currently in phase-1 clinical trials for the study of the safety of chlamydia vaccine CTH522 in healthy women aged 18 to 45 years.

Currently, more than 50% of the pipeline candidates for chlamydia infections are in phase 2 and phase 3 stage. Majority of the studies have been sponsored by research institutes.

Report Description

The report on ‘Chlamydia Infections – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for chlamydia infections. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for chlamydia infections.

The report on ‘Chlamydia Infections – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target


• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration


• Overview of dormant and discontinued pipeline products


• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products


• Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.


• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for chlamydia infections


• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players


• Identify the focus of leading players in relation to R&D for chlamydia infections


• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business


• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary